Comprehensive assessment of multiple tryptophan metabolites as potential biomarkers for immune checkpoint inhibitors in patients with non-small cell lung cancer

Engagement of Nuclear Coactivator 7 by 3-Hydroxyanthranilic Acid Enhances Activation of Aryl Hydrocarbon Receptor in Immunoregulatory Dendritic Cells

(2019) Marco Gargaro et al.   Frontiers in Immunology

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

(2018) Leena Gandhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunomodulatory capacity of the serotonin receptor 5-HT2B in a subset of human dendritic cells

(2018) Attila Szabo et al.   Scientific Reports

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

(2017) Achim Rittmeyer et al.   LANCET

IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance

(2016) David H. Munn et al.   TRENDS IN IMMUNOLOGY

The tryptophan metabolite picolinic acid suppresses proliferation and metabolic activity of CD4+ T cells and inhibits c-Myc activation

(2015) Johanna Prodinger et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting the indoleamine 2,3-dioxygenase pathway in cancer

(2015) Yong Wha Moon et al.   Journal for ImmunoTherapy of Cancer

Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells

(2013) S. Spranger et al.   Science Translational Medicine

Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer

(2009) Yuzo Suzuki et al.   LUNG CANCER

Effect of 3-hydroxyanthranilic acid in the immunosuppressive molecules indoleamine dioxygenase and HLA-G in macrophages

(2008) Ana S. López et al.   IMMUNOLOGY LETTERS